125 related articles for article (PubMed ID: 38100571)
1. Identification of active compounds as novel dipeptidyl peptidase-4 inhibitors through machine learning and structure-based molecular docking simulations.
Ali S; Shaikh S; Ahmad K; Choi I
J Biomol Struct Dyn; 2023 Dec; ():1-10. PubMed ID: 38100571
[TBL] [Abstract][Full Text] [Related]
2. Identification of levomenthol derivatives as potential dipeptidyl peptidase-4 inhibitors: a comparative study with gliptins.
Alade AA; Ahmed SA; Mujwar S; Kikiowo B; Akinnusi PA; Olubode SO; Olufemi OM; Ohilebo AA
J Biomol Struct Dyn; 2024 May; 42(8):4029-4047. PubMed ID: 37261796
[TBL] [Abstract][Full Text] [Related]
3. Structure-based molecular docking and molecular dynamics simulations study for the identification of dipeptidyl peptidase 4 inhibitors in type 2 diabetes.
Chen X; Xue B; Wahab S; Sultan A; Khalid M; Yang S
J Biomol Struct Dyn; 2023 Dec; ():1-14. PubMed ID: 38100564
[TBL] [Abstract][Full Text] [Related]
4. Discovery of Novel DPP-IV Inhibitors as Potential Candidates for the Treatment of Type 2
Musoev A; Numonov S; You Z; Gao H
Molecules; 2019 Aug; 24(16):. PubMed ID: 31394858
[TBL] [Abstract][Full Text] [Related]
5. A combination of virtual screening, molecular dynamics simulation, MM/PBSA, ADMET, and DFT calculations to identify a potential DPP4 inhibitor.
Zare F; Ataollahi E; Mardaneh P; Sakhteman A; Keshavarz V; Solhjoo A; Emami L
Sci Rep; 2024 Apr; 14(1):7749. PubMed ID: 38565703
[TBL] [Abstract][Full Text] [Related]
6. Exploring novel targets of sitagliptin for type 2 diabetes mellitus: Network pharmacology, molecular docking, molecular dynamics simulation, and SPR approaches.
Qi JH; Chen PY; Cai DY; Wang Y; Wei YL; He SP; Zhou W
Front Endocrinol (Lausanne); 2022; 13():1096655. PubMed ID: 36699034
[TBL] [Abstract][Full Text] [Related]
7. Mechanism of molecular interaction of sitagliptin with human DPP
Gonzatti MB; Júnior JEM; Rocha AJ; de Oliveira JS; Evangelista AJJ; Fonseca FMP; Ceccatto VM; de Oliveira AC; da Cruz Freire JE
Adv Med Sci; 2023 Sep; 68(2):402-408. PubMed ID: 37837799
[TBL] [Abstract][Full Text] [Related]
8. A novel artificial intelligence protocol to investigate potential leads for diabetes mellitus.
Gong JN; Zhao L; Chen G; Chen X; Chen ZD; Chen CY
Mol Divers; 2021 Aug; 25(3):1375-1393. PubMed ID: 33687591
[TBL] [Abstract][Full Text] [Related]
9. Identification of diverse dipeptidyl peptidase IV inhibitors via structure-based virtual screening.
Li C; Lu W; Lu C; Xiao W; Shen X; Huang J; Liu G; Tang Y
J Mol Model; 2012 Sep; 18(9):4033-42. PubMed ID: 22460522
[TBL] [Abstract][Full Text] [Related]
10. Pharmacophore- based virtual screening, 3D- QSAR, molecular docking approach for identification of potential dipeptidyl peptidase IV inhibitors.
Shah BM; Modi P; Trivedi P
J Biomol Struct Dyn; 2021 Apr; 39(6):2021-2043. PubMed ID: 32242496
[TBL] [Abstract][Full Text] [Related]
11. Computer-Aided Screening of Phytoconstituents from
Sajal H; Patil SM; Raj R; Shbeer AM; Ageel M; Ramu R
Molecules; 2022 Aug; 27(16):. PubMed ID: 36014373
[TBL] [Abstract][Full Text] [Related]
12. SVMDLF: A novel R-based Web application for prediction of dipeptidyl peptidase 4 inhibitors.
Chandra S; Pandey J; Tamrakar AK; Siddiqi MI
Chem Biol Drug Des; 2017 Dec; 90(6):1173-1183. PubMed ID: 28585374
[TBL] [Abstract][Full Text] [Related]
13. Dipeptidyl peptidase-4 inhibitory potentials of
Shaikh S; Ali S; Lim JH; Chun HJ; Ahmad K; Ahmad SS; Hwang YC; Han KS; Kim NR; Lee EJ; Choi I
Front Mol Biosci; 2022; 9():1024764. PubMed ID: 36250007
[TBL] [Abstract][Full Text] [Related]
14. Dipeptidyl peptidase 4 inhibitors attenuate cardiac ischaemia-reperfusion injury in rats with diabetes mellitus type 2.
Bradic J; Milosavljevic I; Bolevich S; Litvitskiy PF; Jeremic N; Bolevich S; Zivkovic V; Srejovic I; Jeremic J; Jovicic N; Mitrovic S; Jakovljevic V
Clin Exp Pharmacol Physiol; 2021 Apr; 48(4):575-584. PubMed ID: 33352623
[TBL] [Abstract][Full Text] [Related]
15. Identification of a Novel Scaffold for Inhibition of Dipeptidyl Peptidase-4.
Mishra A; Cross M; Hofmann A; Coster MJ; Karim A; Sattar A
J Comput Biol; 2019 Dec; 26(12):1470-1486. PubMed ID: 31390221
[TBL] [Abstract][Full Text] [Related]
16. Structure-based virtual screening of dipeptidyl peptidase 4 inhibitors and their in vitro analysis.
Rahman SU; Ali HS; Jafari B; Zaib S; Hameed A; Al-Kahraman YMSA; Langer P; Iqbal J
Comput Biol Chem; 2021 Apr; 91():107326. PubMed ID: 32739275
[TBL] [Abstract][Full Text] [Related]
17. New Molecular Insights into the Inhibition of Dipeptidyl Peptidase-4 by Natural Cyclic Peptide Oxytocin.
Chittepu VCSR; Kalhotra P; Osorio-Gallardo T; Jiménez-Martínez C; Torre RRR; Gallardo-Velazquez T; Osorio-Revilla G
Molecules; 2019 Oct; 24(21):. PubMed ID: 31661941
[TBL] [Abstract][Full Text] [Related]
18. A time-resolved fluorescence probe for dipeptidyl peptidase 4 and its application in inhibitor screening.
Kawaguchi M; Okabe T; Terai T; Hanaoka K; Kojima H; Minegishi I; Nagano T
Chemistry; 2010 Dec; 16(45):13479-86. PubMed ID: 20938933
[TBL] [Abstract][Full Text] [Related]
19. Design and synthesis of 4-(2,4,5-trifluorophenyl)butane-1,3-diamines as dipeptidyl peptidase IV inhibitors.
Zhu L; Li Y; Qiu L; Su M; Wang X; Xia C; Qu Y; Li J; Li J; Xiong B; Shen J
ChemMedChem; 2013 Jul; 8(7):1104-16. PubMed ID: 23671024
[TBL] [Abstract][Full Text] [Related]
20. In silico screening of chalcone derivatives as promising EGFR-TK inhibitors for the clinical treatment of cancer.
Mathpal S; Joshi T; Sharma P; Maiti P; Nand M; Pande V; Chandra S
3 Biotech; 2024 Jan; 14(1):18. PubMed ID: 38130684
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
